Form 4: Hologic exec withholds shares for RSU taxes

Hologic’s Diagnostic Solutions President Jennifer M. Schneiders withheld 561 shares to cover taxes on vested RSUs, leaving 41,318 shares owned directly.

Summary

• On 2025-11-14, officer Jennifer M. Schneiders (President, Diagnostic Solutions) reported a tax withholding transaction (code F) involving 561 shares of Hologic, Inc. common stock at $74.15 per share.
• Purpose of the transaction: shares withheld to satisfy tax obligations upon settlement of vested restricted stock units (service-based vesting satisfied).
• Post-transaction direct beneficial ownership stands at 41,318 Hologic shares.
• No open-market purchase or sale occurred; this was a non-discretionary administrative withholding tied to RSU vesting.
• Form signed by attorney-in-fact on 2025-11-18.

Sentiment

Score: 5

Explanation: Neutral, routine administrative insider transaction for tax withholding with no bearing on operating performance or strategy.

Positives

• No open-market sale by the executive; shares were withheld solely for taxes on RSU vesting (non-discretionary).
• Executive continues to hold 41,318 shares post-transaction, indicating ongoing equity alignment.
• Transparency on equity compensation events and associated tax treatment.

Negatives

• Minor reduction in insider share count (561 shares) due to tax withholding.
• No incremental information on operating performance, outlook, or strategy.

Future Outlook

No forward-looking statements or guidance provided; this is an administrative insider transaction related to tax withholding on RSU vesting.

Management Comments

• “Shares withheld for tax obligations in connection with the settlement of restricted stock units for which service-based vesting requirements have been satisfied.”

Industry Context

Routine tax-withholding transactions upon RSU vesting are common across medtech and broader S&P 500 companies and typically carry no implications for company fundamentals or strategy.

Comparison to Industry Standards

• Consistent with common practice at large-cap medtech peers (e.g., Abbott, Danaher, Thermo Fisher) where executives routinely report code F RSU tax withholdings.
• Transaction size (hundreds of shares) fits the normal range for periodic RSU vesting events at comparable companies.
• No deviation from standard insider reporting norms under Section 16; timing and disclosure align with industry best practices.

Stakeholder Impact

• Shareholders: No material impact; administrative withholding does not signal insider sentiment.
• Employees: Confirms ongoing equity compensation and vesting processes.
• Market: No open-market activity; minimal relevance for valuation.

Key Dates

Keywords

Hologic, HOLX, Form 4, insider transaction, restricted stock units, RSU vesting, tax withholding, Jennifer M. Schneiders, medical technology, diagnostic solutions